Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. - Wikidata - wikimedia - TriplyDB

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

http://www.wikidata.org/entity/Q37842346

about

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation.Proteasome inhibitors in acute leukemia.Immune reconstitution inflammatory syndrome associated with bacterial infections.Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review.Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma.(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.

P2860

Q33429980-A66D3850-A0FC-4CE9-A23B-1D1857CE4039 Q36675330-C440430E-A373-4896-BF94-AF45C436C660 Q38088003-72F2EBBB-B20A-4E9A-BA77-1463F7CFFE04 Q38186797-C6CE0F7F-C876-4490-A6A0-CE99B0642EC9 Q39034873-461F9189-BB80-4924-9DC3-F0FD8CF5CA7E Q39425529-E44C03B6-4524-4F17-A164-4CF1BE5628FA Q40795146-E22F6C7A-39F8-4A2E-9855-575FA8D10A9D Q47407841-D807B9FC-D9CF-484D-A398-D37646C0BD2A Q49660927-866646D4-6E21-404A-842A-64DC7DE016FA

P2860

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

http://www.wikidata.org/entity/Q37842346

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Thalidomide, lenalidomide and ...... ly diagnosed multiple myeloma.

@en

Thalidomide, lenalidomide and ...... ly diagnosed multiple myeloma.

@nl

type

label

Thalidomide, lenalidomide and ...... ly diagnosed multiple myeloma.

@en

Thalidomide, lenalidomide and ...... ly diagnosed multiple myeloma.

@nl

prefLabel

Thalidomide, lenalidomide and ...... ly diagnosed multiple myeloma.

@en

Thalidomide, lenalidomide and ...... ly diagnosed multiple myeloma.

@nl

P1433

Q37842346-AF74E98E-19F7-483D-929B-BE78B70299AB

P1476

Q37842346-033442D1-7957-43D7-ABED-27DF34B304CC

P2093

Q37842346-03227759-D2E0-40F2-A466-DB5F35A07249

Q37842346-6A868AB9-4D39-4093-AEF4-8638ED1FEA81

Q37842346-AF7AD8A7-780C-4B25-9592-0DC9C2D194B8

P2860

Q37842346-00060F27-8B88-4CC0-ADF9-E2F942A03C41

Q37842346-0808B0DB-F987-4B5C-82E4-653880723486

Q37842346-0A750CB9-CB9D-4EC6-976E-C440AAFB26C1

Q37842346-0AF8AD90-656A-49B2-9C3C-6EBC31329960

Q37842346-102AD9AE-B82D-40B9-9470-DA4E0E05A126

Q37842346-12B63C25-AD24-42B6-93E5-CE7285E20413

Q37842346-15C66BC7-C839-462F-B2B7-19F6E22D5C4B

Q37842346-171ECB30-7CE7-4C58-ACF9-1C441EB9212D

Q37842346-178C158D-CB6D-477E-AB57-582C4DDEC760

Q37842346-178D63B1-FA47-4A90-BE3D-06F75D53CE44

P304

Q37842346-848A9388-6BC0-4502-8013-B79C3808F71A

P31

Q37842346-C38F148F-E792-4ACE-ABAB-5E5FE7781B43

P356

Q37842346-E4A949F7-D16B-4778-A7E1-EA84B794ACA6

P433

Q37842346-58649FA7-CC43-4380-91A0-5B3145462E85

P478

Q37842346-C7704E0D-519F-4165-A7F3-9F13D47D4E91

P50

Q37842346-5B809569-B3FC-4213-8275-E8A4EEA8FD58

Q37842346-5F549566-2ACD-4178-A7D1-15D43C059891

P577

Q37842346-66991871-261A-407F-B89B-9AF0F94B5FBC

P698

Q37842346-6A3B26BE-437E-43C4-B36B-2DF88DF91831

P921

Q37842346-68F5C9AD-EA30-4D8D-AA2B-AF32490905A9

P356

P1433

Expert Review of Hematology

P1476

Thalidomide, lenalidomide and ...... ly diagnosed multiple myeloma.

@en

P2093

Constantine S Mitsiades

http://www.w3.org/2001/XMLSchema#string

Jacob P Laubach

http://www.w3.org/2001/XMLSchema#string

Robert L Schlossman

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide is an inhibitor of angiogenesis

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

Cancer statistics, 2008

Thalidomide therapy and deep venous thrombosis in multiple myeloma

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.

P304

51-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/EHM.10.83

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21322778

http://www.w3.org/2001/XMLSchema#string

P921